Specifically, PTPN2 is implicated in the subtype specificity of breast cancer, and low expression in patients with Luminal A and HER2-positive tumors is linked to a higher recurrence rate, but not in patients with triple-negative tumors (28). This evidence concerns the gene ERBB2 and breast cancer.